Monoclonal antibody

Asia deal flurry draws AZ, Spero to $1B+ Dizal, Innovent assets

Tue, 21 Jul 2026 11:00:00 -0400

Another day, another two multibillion-dollar deals with Asian companies, this time involving Dizal Pharmaceutical Co. Ltd. and its EGFR inhibitor for lung cancer, as well as Innovent Biologics Inc. and its anti-CD40L antibody for a chronic fibroinflammatory condition.

Asia deal flurry draws AZ, Spero to $1B+ Dizal, Innovent assets

Tue, 14 Jul 2026 12:00:00 -0400

Forte, First Tracks soar on CD122 success in vitiligo; celiac next

Thu, 09 Jul 2026 12:00:00 -0400

Encouraging phase I data this week of new treatments for vitiligo, a chronic autoimmune disorder that destroys melanocytes, drove investor excitement, with Forte Biosciences Inc. the latest company to disclose a statistically significant benefit.

Trex Bio discloses TRB-071 as CD30 agonist antibody

Wed, 01 Jul 2026 09:00:00 -0400

Trex Bio Inc. has disclosed that its development candidate TRB-071, currently in IND-enabling studies, is a CD30 agonist antibody. The approach could have therapeutic potential in inflammatory bowel disease and other autoimmune and inflammatory diseases.

Samsung Bioepis’ Keytruda biosimilar hits phase I, III endpoints

Tue, 30 Jun 2026 08:00:00 -0400

Samsung Bioepis Co. Ltd. announced positive top-line phase I and phase III data for SB-27, a proposed biosimilar to Merck & Co. Inc.’s blockbuster immunotherapy Keytruda (pembrolizumab). Preliminary analysis of parallel-run global phase I and phase III studies demonstrated SB-27’s clinical and pharmacokinetic (PK) equivalence to the reference product, according to a company announcement.

Samsung Bioepis’ Keytruda biosimilar hits phase I, III endpoints

Mon, 29 Jun 2026 12:00:00 -0400

Regeneron reports TSHR-blocking MAb for Graves’ disease

Fri, 26 Jun 2026 09:00:00 -0400

Graves’ disease is a form of autoimmune hyperthyroidism where the main extrathyroidal feature is thyroid eye disease. Autoantibodies that stimulate thyroid-stimulating hormone receptor (TSHR) are released and orchestrate hormone production in the thyroid tissue and the orbit. Regeneron Pharmaceuticals Inc. has developed REGN-24493, a monoclonal antibody (MAb) that binds TSHR and blocks its activation by those autoantibodies.

Lys Therapeutics advances LYS-241

Tue, 23 Jun 2026 09:00:00 -0400

Lys Therapeutics SAS is advancing LYS-241 toward the clinic with the support of more than €25 million (US$33 million) in funding raised since the company’s inception in 2021. The financing includes a grant of more than $5 million from The Michael J. Fox Foundation.

Bionyra closes $165M series A to develop antibodies for inflammation

Mon, 22 Jun 2026 12:00:00 -0400

Bionyra Pharma has emerged with a $165 million oversubscribed series A and a portfolio of three antibodies with extended half-lives that are designed to offer improvements over existing classes of monoclonal antibodies for treating chronic inflammatory diseases.

Abbvie pads immunology pipeline in $10.9B Apogee buy

Mon, 22 Jun 2026 12:00:00 -0400

In a deal viewed as a big win for both companies, Abbvie Inc. is buying Apogee Therapeutics Inc. for $10.9 billion. The transaction calls for shareholders of Apogee to receive $135.11 per share in cash, marking a nearly 50% premium over Friday’s closing stock price, and puts lead candidate zumilokibart, a late-stage, half-life extended monoclonal antibody targeting IL-13 that has shown competitive phase II data in atopic dermatitis, in the hands of a pharma giant with a well-established immunology franchise.

Avalo Therapeutics advances AVTX-010 for hidradenitis suppurativa

Tue, 16 Jun 2026 09:00:00 -0400

Avalo Therapeutics Inc. is advancing AVTX-010, a long-acting next-generation anti-IL-1β monoclonal antibody with potential for hidradenitis suppurativa and additional inflammatory disorders

No CNPV needed? Sanofi’s Tzield gains accelerated nod in stage 3 T1D

Mon, 15 Jun 2026 12:00:00 -0400

Despite some back-and-forth with the U.S. FDA regarding inclusion in the somewhat controversial Commissioner’s National Priority Voucher (CNPV) program, Sanofi SA’s Tzield (teplizumab) gained FDA clearance, expanding use of the CD3-directed monoclonal antibody as a disease-modifying therapy for patients with recently diagnosed stage 3 type 1 diabetes (T1D).

Ethyreal launches to treat the underlying cause of Graves’, TED

Thu, 11 Jun 2026 12:00:00 -0400

Ethyreal Bio Inc. has come out of stealth mode in order to disclose preclinical data for ETHY-001, its monoclonal antibody targeting thyroid stimulating hormone receptor, at the Endocrine Society’s 2026 annual meeting on June 15.

Ethyreal Bio launches with focus on thyroid diseases

Thu, 11 Jun 2026 09:00:00 -0400

Ethyreal Bio Inc. has launched with $101 million in financing and a focus on developing precision therapies for thyroid diseases with high unmet need.

Sanofi phase III CIDP quit dents Dianthus; C1 mismatch?

Wed, 10 Jun 2026 12:00:00 -0400

Investors in Dianthus Therapeutics Inc. apparently chose to ignore subtleties in the difference between efforts with that firm’s claseprubart vs. those by competitor Sanofi SA, which said that the phase III Mobilize study testing riliprubart in chronic inflammatory demyelinating polyneuropathy (CIDP) will be stopped for futility.

Incyte nabs potential VWD game-changer in Vega deal; J&J buys Firefly

Mon, 08 Jun 2026 12:00:00 -0400

In its largest acquisition to date, Incyte Inc. snagged rights to phase III-stage VGA-039, a monoclonal antibody the firm said could offer a new standard of care in von Willebrand disease (VWD), in a buyout of Vega Therapeutics Inc. that includes a $1.25 billion up-front payment and up to $750 million tied to the achievement of sales milestones. The announcement was followed shortly by news of another buyout, Johnson & Johnson’s deal to acquire Firefly Bio Inc. for $1 billion in cash, both moves continuing this year’s trend of larger, more strategic M&A transactions.

Ona raises $86.6M series B for ADCs to treat advanced cancers

Thu, 04 Jun 2026 12:00:00 -0400

Antibody-drug conjugate (ADC) specialist Ona Therapeutics SL has closed an oversubscribed series B at $86.6 million, as clinical development of the lead program ONA-255 in advanced treatment-resistant breast cancer gathers steam.

ADCs, multispecific antibodies anchor $10B Pfizer-Innovent deal

Tue, 02 Jun 2026 12:00:00 -0400

Pfizer Inc. is paying Innovent Biologics Co. Ltd. $650 million up front and up to $9.85 billion in milestones, plus royalties, to collaborate across 12 early stage and de novo antibody-drug conjugates (ADCs) and multispecific antibodies for oncology.

ADCs, multispecific antibodies anchor $10B Pfizer-Innovent deal

Fri, 29 May 2026 12:00:00 -0400

WHO selects vaccines, therapeutics for Ebola outbreak field trials

Fri, 29 May 2026 12:00:00 -0400

“I need to be honest with you about something important. Most previous Ebola outbreaks in the Democratic Republic of Congo (DRC) were caused by a virus called Ebola Zaire, for which we have vaccines and treatments. This outbreak is caused by a different virus called Ebola Bundibugyo. There are currently no approved vaccines or treatments for it.” This was the stark message from Tedros Adhanom Ghebreyesus, director general of the World Health Organization (WHO) in an open letter to the people of the DRC, as he traveled to the country on Friday, May 29.

Apogee orbiting big AD market as Apex phase II data land

Wed, 27 May 2026 12:00:00 -0400

Apogee Therapeutics Inc. loaded up on what could total as much as $1.3 billion in financial fuel from Blackstone Life Sciences funds that will be used to propel zumilokibart (zumi), which yielded positive phase II results in atopic dermatitis (AD). A phase III experiment with the anti-IL-13 antibody is planned for the second half of this year, pending talks with regulators.

Infex has positive phase IIa data in bronchiectasis; preps for next trial

Thu, 21 May 2026 12:00:00 -0400

Infex Therapeutics Ltd. has published positive phase IIa data for its lead program, RESP-X, in the treatment of exacerbations of chronic respiratory infections caused by Pseudomonas aeruginosa and is now laying the ground for phase IIb development, after raising £4.3 million (US$5.8 million) in new capital.

Immunovant rises on IMVT-1402 data in difficult-to-treat RA

Wed, 20 May 2026 12:00:00 -0400

Shares of Immunovant Inc. (NASDAQ:IMVT) gained 35% after the firm disclosed early but “compelling” data from a phase IIb study testing next-generation FcRn inhibitor IMVT-1402 in patients with difficult-to-treat rheumatoid arthritis (D2T RA), including those whose disease has persisted despite treatment with TNF and JAK inhibitors.

Re-Aim Therapeutics launches with focus on autoimmune diseases

Wed, 20 May 2026 09:00:00 -0400

Re-Aim Therapeutics Ltd. has launched with £7 million (US$9.4 million) in seed investment backing and a focus on developing functional cures for T-cell-mediated autoimmune diseases.

Harbour Biomed’s LET-003 shows promise for obesity

Mon, 18 May 2026 09:00:00 -0400

Harbour Biomed has released preclinical data for LET-003, a next-generation ACVR2A/2B-targeted monoclonal antibody with potential for the treatment of obesity. Activin receptors ACVR2A and ACVR2B play critical roles in regulating muscle-fat metabolic homeostasis.

Biogen AD drug shows tau, cognition benefit, despite trial miss

Thu, 14 May 2026 12:00:00 -0400

Biogen Inc. has decided to advance diranersen (BIIB-080) into registrational trials for early Alzheimer’s disease, even though the antisense oligonucleotide therapy, originally discovered by Ionis Pharmaceuticals Inc., missed its phase II primary endpoint.

Curacle, Memento ink $1B deal for ocular TIE2/VEGF bispecific

Tue, 12 May 2026 12:00:00 -0400

Curacle Co. Ltd. inked a potential $1.07 billion deal with U.S.-based “newco” Memento Medicines on May 10, granting the latter exclusive global rights to develop and commercialize preclinical TIE2/VEGF-directed bispecific antibody MT-103 for retinal disorders.

Curacle, Memento ink $1B deal for ocular TIE2/VEGF bispecific

Tue, 12 May 2026 09:00:00 -0400

Curacle, Memento ink $1B deal for ocular TIE2/VEGF bispecific

Mon, 11 May 2026 12:00:00 -0400

Singlomics’ DXP-106 shows robust results in preclinical setting

Mon, 11 May 2026 09:00:00 -0400

The interleukin-1 receptor accessory protein (IL1RAP) is expressed in cancer cells within the tumor microenvironment of several cancer types and plays a role in tumor development. DXP-106 is a humanized monoclonal antibody developed by Singlomics Biopharmaceuticals Co. Ltd. that binds to a unique epitope of IL1RAP domain 2 that competes with cytokines.